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Background: Mobile health may be used to generate innovative insights into optimizing 220 
treatment to improve allergic rhinitis control.   221 
Objectives: A cross-sectional real world observational study was undertaken in 22 countries to 222 
complement a pilot study and bring novel information on medication use, disease control and 223 
work productivity in everyday life of patients with allergic rhinitis. 224 
Methods: A mobile phone app (Allergy Diary, freely available Google Play and Apple stores) 225 
was used to collect data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, 226 
(ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a 227 
treatment scroll list including all allergy medications (prescribed and over-the-counter (OTC)) 228 
customized for 22 countries. The four most common intra-nasal medications containing intra-229 
nasal corticosteroids and eight oral H1-antihistamines were studied. 230 
Results: 9,122 users filled in 112,054 days of VAS in 2016 and 2017. The assessment of days 231 
was informative. The control of days with rhinitis differed between no [best control], single 232 
[good control for intranasal corticosteroid-treated days] or multiple treatments [worst control].  233 
Users with the worst control increased the range of treatments being used. The same trend was 234 
found for asthma, eye symptoms and work productivity. Differences between oral H1-235 
antihistamines were found.  236 
Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and 237 
assessing patient behavior in allergic rhinitis. This observational study using a very simple 238 
assessment tool (VAS) on a mobile phone had the potntial to answer questions previously 239 
thought infeasible. 240 














Capsule summary  242 
Most rhinitis patients use on-demand treatment when t y are not controlled. Control was worse 243 
with increasing medications. Real life data may not be aligned with guidelines. 244 
Clinical implications  245 
A behavioural disconnection was found in the study since patients are not adherent to treatment 246 
and treat themselves on-demand when they are not controlled whereas the vast majority of 247 
physicians prescribe long-term treatment to achieve control. Shared-decision making is 248 
essential. 249 
 250 
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Introduction  274 
The treatment of allergic rhinitis (AR) is complex as many drugs are available in oral and/or 275 
topical formulations. Many guidelines for AR are evidence-based and have led to a better 276 
management of AR.  However, guidelines are mostly based on randomized controlled trials 277 
(RCTs), typically undertaken on highly selected populations, often with limited/unclear 278 
generalizability to routine care contexts (1, 2). They propose to increase treatment to achieve 279 
disease control (i.e. sleep, social and school/work impairment) that is the ultimate aim of the 280 
treatment. Intra-nasal corticosteroids represent the most effective AR treatment for most 281 
patients, but their effect is relatively slow, taking several hours (3) and many patients prefer oral 282 
medications. A formulation of fluticasone propionate (FP) and azelastine (AzeFlu) is more 283 
effective than INCS alone (4) and has the advantage of acting within minutes (5). Patients are 284 
poorly adherent to treatment and often self-medicate (6, 7). They want more effective and fast 285 
acting treatments. Observational real-life studies are therefore needed to complement RCTs in 286 
order to better understand the efficacy of INCS-containing medications since they do not select 287 
patients and report their behavior.  288 
MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis), an information and 289 
communications technology (ICT) system centered around the patient (8-12) operational in 23 290 
countries, uses a treatment scroll list including all medications customized for each country and 291 
a visual analogue scales (VAS) to assess rhinitis control. A pilot study in over 2,900 users 292 
allowed differentiation between treatments (13). Patients did not necessarily use treatment on a 293 
daily basis in a regular way but appeared to increase treatment use when their symptom’s 294 
control worsens. However, the pilot study needs to be confirmed with a larger number of users 295 
and more medications tested. 296 
The present cross-sectional observational study was undertaken in 9,122 users in 22 countries 297 
(data collection was just started in Argentina) to confirm the pilot study (13) using the same 298 
methods and to bring novel information on medication use, and associated disease control, work 299 
productivity (14) and allergic multimorbidity (13). The study was focused firstly on the four 300 
most commonly used intra-nasal medications containing intra-nasal corticosteroids: Fluticasone 301 
Furoate (FF), Fluticasone Propionate (FP), Mometasone Furoate (MF) and AZeFlu. We did not 302 
perform the same analysis with oral H1-antihistamines as they are often associated with INCS 303 
and many patients would have been analysed twice.  In the second analysis, we examined some 304 
widely used oral H1-antihistamines: Bilastine, Cetirizine (CET), Desloratadine (DL), Ebastine, 305 
Fexofenadine (FEXO), Levocetirizine (LEVOCET), Loratadine (Lora) and Rupatadine. In the 306 
first analysis, we compared days with single treatment with days with multiple treatments. In 307 















Users  310 
All consecutive users from January 1, 2016 to December 31, 2017 were included with no 311 
exclusion criteria according to methods previously described (13, 14). 312 
Setting 313 
Users from 22 countries filled in the Allergy Diary (Table 1). Data collection was just started in 314 
Argentina and not included 315 
Ethics 316 
The Allergy Diary is CE1. CE marking is a certification mark that indicates conformity with 317 
health, safety, and environmental protection standards for products made in the EU and meets 318 
the essential requirements of all relevant European Medical Device Directives (15). CE1 319 
includes sterile and non-sterile products and assess whether the device has a measuring 320 
function.   321 
The data were anonymized including data related to geolocalization using k-anonymity (16).  322 
An independent Review Board approval was not requird since the study is observational and 323 
users agreed to have their data analysed (terms of u e).  324 
Allergy Diary 325 
Geolocalized users assess their daily symptom control using the touchscreen functionality on 326 
their smart phone to click on five consecutive VAS scores (i.e. general, nasal and ocular 327 
symptoms, asthma and work). Users input their daily medications using a scroll list which 328 
contains all country-specific OTC and prescribed medications available for each country (Figure 329 
1 online). The list has been populated using IMS data. 330 
Days reported by users included days with or withou treatment. 331 
The present study is another Allergy Diary study. Some of the raw data used in the first paper 332 
(up to November 2016) (13) were used in this study, but analyses differed.  333 
Selection of medications 334 














(17). Monotherapy was defined as days when only one si gle medication for rhinitis was 336 
reported. AzeFlu contains two drugs but, as it is a fixed combination it was considered as 337 
monotherapy. Co-medication was defined as days witht o or more medications for rhinitis. 338 
Asthma medications were not considered in co-medication.   339 
 Size of the study 340 
In this study, all registered users were included to obtain the best possible estimates for the 341 
specified time window. From the pilot study, numbers tested largely exceed those needed to 342 
find significant differences in the full set analysis (13).  However, we did not consider 343 
medications with a sample size under 1,000 days of reporting. 344 
Statistical methods  345 
A non-Gaussian distribution was found for the data. Non-parametric tests and medians (and 346 
percentiles) were used. Correction for multiple testing was made when appropriate.  347 
Some users reported VAS scores more than once a day. In the pilot study, we found that the 348 
highest reported value should be used and we followed this study (13). We however tested in an 349 
exploratory analysis VAS levels in duplicates and multiplicates.  350 
Analysis of the data 351 
We conducted, as previously published (13), separate analyses using the full-set of data and data 352 
on just the first day of reporting. 353 
In the first analysis, only users who reported no treatment or treatment by the intra-nasal FF, FP, 354 
MF and AZeFlu were studied (Figure 2 online). Those receiving other INCS were excluded. For 355 
co-medication, we initially selected second generation oral H1-antihistamines (OAH): CET, 356 
DL, Ebastine, FEXO, LEVOCET, LORA and Rupatadine (Group + OAH). There are many 357 
other OAH, but we did not consider them since their pharmacologic properties vary widely and 358 
they were not often used. We considered two other groups in INCS users for co-medication: 359 
users who reported OAH and another medication (Group OAH + other) and users who reported 360 
another medication (+ Other). Users who reported other medications but no INCS were not 361 
analyzed. As a primary end point, using the full data set, we studied median VAS global 362 
measured (“Overall how much are your allergic symptoms bothering you today?”) levels for 363 
days with FF, FP, MF and AZeFlu and for days without medications. The primary and 364 
secondary end points were analyzed using the Kruskal-Wallis test and Wilcoxon and Mann-365 














Moreover, we analysed the data using three cutoffs: VAS <20/100 (controlled days), VAS 20-367 
49 (days with moderate control), VAS ≥50 (days with poor control) according to a consensus 368 
(18) and available data of the pilot study (13, 14). The same analyses were conducted for the 369 
first day of VAS report. Secondary end-points included VAS eye, asthma and work.  370 
In the second analysis, we compared days with monotherapy for the most common OAH: CET, 371 
DL, Ebastine, FEXO, LEVOCET, LORA and Rupatadine monotherapy. We did not consider 372 
other OAH with a sample size under 1,000 days (or close to this number). We only compared 373 
VAS global measured. The mean number of days of reporting was considered for each 374 
treatment.  375 
We then performed exploratory analyses to investigate whether there are temporal patterns in 376 
the reporting of VAS in the app users. We assessed the VAS levels on: (i) days with more than 377 
1 VAS reported, (ii) the first day of reporting and first day of new reporting in users with non-378 
consecutive data, (iii) days without treatment followed by a day with treatment and (iv) days 379 
with treatment followed by a day without treatment. 380 
Results  381 
Demographic characteristics  382 
The study included 9,122 users. Roughly 5% of users did not report their age and were ascribed 383 
to “zero”. Users ranged in age from zero to 92 years (mean, SD: 32.4 ± 15.2 years). There were 384 
54.7% women and 45.3% men. The age repartition is given in Figure 3 online.  385 
A total of 112,054 days was recorded. Duplicates or multiplicates for the same day were found 386 
in 14,767 days. Global VAS was not recorded in 754 (0.8 %) days with App data reported. 387 
There were 52,706 (54.6%) days without treatment and 18,117 days with the targeted INCS 388 
(Figure 1).  389 
Analysis of VAS global measured 390 
On visual inspection, no clear trajectory of VAS could be easily identified, as users reported 391 
erratically their VAS and treatment data. Figure 4 online reports trajectories for French users as 392 
an example.  393 
In the figure each user is identified by a member identifier number (vertical axis) and each 394 















Results are reported in Table 2, Figures 2 and 3. 397 
Analysis of VAS global measured on days without treatment and days with INCS 398 
treatment 399 
The first day of reporting, VAS levels were reported by 4,991 users without treatment, 1,395 users 400 
with OAH and 1,281 users with INCS treatment (Table 2). The percentage of users with single 401 
treatment ranged from 34.0% (FP), 39.2% (MF), 40.5% (FF) and 59.6% (AzeFlu). Days with INCS 402 
alone had similar median VAS levels (35 to 44).  403 
For the full data set of 96,533 days, VAS levels were r ported by 6,236 users without treatment, 3,664 404 
users with OAH and 2,575 users with INCS treatment (Table 2). Monotherapy was reported 45 to 55% 405 
of the days (FF or MF versus AzeFlu – Figure 2). For m notherapy, median VAS levels ranged from 5 406 
(FF) to 23.5 (FP). For day 1 and the full data set,the same trend was found in INCS treated users: 407 
lowest median levels were found for monotherapy, increased levels with co-medication by OAH and 408 
highest levels for co-medication with OAH + other treatments (Figure 3). Variable levels of VAS were 409 
observed for co-medication with other treatments. The numbers of days of co-medication with another 410 
INCS are too low to make any comparison (Table 2).  411 
Analysis of VAS global measured on days with OAH treatment alone 412 
The first day of reporting, days with no treatment or those with INCS in monotherapy had similar 413 
median VAS levels (34 to 44). On the other hand, there were some variations for OAH in 414 
monotherapy. LEVOCET days had a median VAS level intermediate between untreated or INCS-415 
treated days and the other OAH. For the full data se  of 96,533 days, median VAS levels of days with 416 
INCS were lower than those of days with OAH but Bilastine, FEXO, LEVOCET and Rupatadine had 417 
levels similar to those of INCS (Table 2).  418 
Apart from days with FP treatment (low numbers), the mean numbers of days of reporting medications 419 
per user ranged from 4.00 (CET) to 8.98 (AzeFlu).    420 
Analyses of VAS for eye, asthma and work 421 
Analyses of VAS eye, asthma and work are reported in Figures 5A, B and C online supplement. 422 
Trends for the three secondary end points are similar to those of VAS global measured, i.e. low 423 
median levels similar to untreated days for the single treatment, increased levels with co-424 
medication by OAH and highest levels for co-medication with OAH + other medication, and the 425 
highest percentage of users with single treatment observed for AzeFlu. Fewer users reported 426 














Exploratory analyses investigating potential temporal patterns in the reporting of 428 
VAS  429 
Assessment of duplicates or multiplicates for day 1  430 
Days with 2 or more VAS levels reported at least 1 hour apart within the same day were 431 
selected. The dataset included 1,576 days for VAS global measured. A significantly higher VAS 432 
was found at second reporting compared to the first. When the data were stratified by the type of 433 
treatment recorded at first entry (no treatment, AzeFlu FF, MF and FP), these findings were 434 
only significant for days with no treatment. No difference was found for days with (any) 435 
treatment (Table 1 online). 436 
VAS levels depending on consecutive and non-consecutive data 437 
There were 4,132 users with at least two non-consecutiv  calendar days of VAS reported 438 
(n=89,473 days in total). The global VAS levels measured on day 1 were found to be 439 
significantly higher when compared to the global VAS levels measured on the first day of new 440 
reporting (i.e. or first non-consecutive calendar dy reported), regardless of the presence/type of 441 
treatment (Table 3).  442 
The distribution of global VAS on the 391 consecutive couple of calendar days consisting of a 443 
day without treatment followed by a day with treatment showed a non-significant increased 444 
level in treated days (median [p25-75] =23 [11-49] to 28 [14-50], (p=0.07, Wilcoxon W test). 445 
The distribution of global VAS on the 350 consecutive couple of calendar days consisting of a 446 
day with treatment followed by a day without treatment showed a significant decreased level in 447 
untreated days (median [p25-75] =23 [13-45] to 20 [9-38], (p=0.01 Wilcoxon W test). 448 
Discussion 449 
A pilot study using a very simple assessment (VAS) on a cell phone in 2,871 users who filled in 450 
17,091 days suggested that an App may give novel information concerning the treatment of AR 451 
(13). However, the sample size was possibly too small to draw definite conclusions. This study 452 
in a larger sample (9,111 users in 22 countries, 97,287 days) confirms the findings of the pilot 453 
study showing that, in real life, the assessment of days can inform on patient’s treatment and 454 
bring novel insight on the behaviour of AR patients towards treatment and novel concepts for 455 
change management of AR (19). The control of days differs between no treatment (best 456 
control), single treatment or co-medication (worst control). This study showed for the first time 457 
that the same trends were observed for global sympto s, ocular symptoms, asthma and work 458 














range of treatments was increased in those with poor c ntrol whereas, according to guidelines, 460 
physicians are recommended to increase the treatment o achieve control. This major gap in AR 461 
treatment may explain the overall low level of satif ction of severe AR patients reported in 462 
many studies.  463 
Strengths and limitations 464 
The current study has many strengths including larger numbers, multiple countries, range of 465 
treatments studied and patient/person-generated data. 466 
As for all studies using participatory data, potential biases include (i) the likelihood of sampling 467 
bias likely present, difficult to assess generalizability of the study, (ii) outcome misclassification that 468 
cannot be assessed and, by definition due to ethical problems, there very little information on patien 469 
(or day) characteristics. App users are not representative of all patients with rhinitis. The issue of 470 
potential selection bias was limited by the fact that we considered days and not patients in the 471 
analyses. 472 
As in other studies (13, 20), we used days in a cross-sectional analysis because there is no clear 473 
pattern of treatment and a longitudinal study was not feasible since users mostly use the App 474 
intermittently. Although this observation may differ from RCTs, our study is a real-life 475 
approach.  476 
For this study, other biases should be considered. The diagnosis of AR was not supported by a 477 
physician but was a response to the question: “Do you have allergic rhinitis? Yes/No”. There 478 
may therefore be some users with non-allergic rhinitis who may have responded “Yes” to the 479 
question. There are potential measurement biases when using apps including collection of 480 
information, education of the patient, availability and ability to use a smartphone (13).  Users 481 
self-identified themselves as having AR without confirmation of the diagnosis. Precise patient 482 
characterization is impossible using an App, but every observational study using the Allergy 483 
Diary was able to identify days with poor control or criteria of severity (20-24).  Adherence to 484 
treatment is impossible to prove as users do not report data all days and users may not report all 485 
medications used. Nonetheless, mobile technology is becoming an important tool to better 486 
understand and manage AR and brings novel information that were not available with other 487 
methods (20-26).  488 
Asthma was assessed using a single VAS largely validated in rhinitis (27). In asthma, VAS was 489 
shown to be an effective measure of control (28). In the present study, we did not investigate 490 














may have misunderstood the question or overestimated th  disease. However, the results are 492 
extremely consistent.  493 
We only considered days and not patients’ trajectories because these are highly variable, 494 
patients using auto-medication depending on AR control as previously shown (13). 495 
Longitudinal capture is very challenging with this App but this appears to be the case for all 496 
Apps. Patient’s engagement with digital health in real world scenarios is usually lower than in 497 
RCTs. Although this is a limitation in relation to causal inference, it suggests that a new 498 
methodological approach is needed. It appears that tre tment trajectories are specific for almost 499 
each user and most users have gaps in their treatment wh n they are well controlled.  500 
Interpretation of the results and generalizability 501 
This real world assessment of the Allergy Diary using VAS allows assessment of treatment 502 
efficacy by days, which represents real-life estimaon of AR control and likely reflects real-life 503 
better than patients’ assessments at regular intervals since (i) it is known that AR is a highly 504 
variable disease, and control varies widely between days in relation to allergen and 505 
environmental exposure, (ii) patients are rarely adherent to their treatment, (iii) patients often 506 
stop treatment when they feel better and (iv) patients increase their treatment when 507 
uncontrolled. 508 
VAS scores were greater on days with treatment thanon days without treatment. This study 509 
confirms the study of the pilot one (13) in which, median VAS levels on days without treatment 510 
were similar in users who never reported any medication use and in those who were 511 
occasionally treated. Moreover, in a small sample, it was found that consecutive days under 512 
treatment are less well controlled than days without treatment.  In INCS-treated users, days with 513 
a single treatment were better controlled than days with multiple treatments. An important 514 
message from this paper is that, overall, in real life, patients treat themselves when they suffer 515 
from symptoms and stop their treatment when they ar controlled. This accords with previous 516 
data (29, 30). This study, using objective data, confirmed that adherence is poor. Most AR 517 
patients may have mild and/or intermittent disease that does not need a regular treatment to 518 
achieve control. The concept of pro-active medication and patient participation (31) - the patient 519 
starting treatment when experiencing symptoms and continuing for a few days after getting 520 
control -  may be of great interest and could be tested with the App. In asthma, self-guided 521 
treatment was found to be of interest (31-33). Such real-life findings may ultimately affect the 522 
way in which guidelines are constructed to align them more with human behaviour. We have 523 














we propose to develop next-generation care pathways and test the recommendations of GRADE 525 
guidelines in AR (3, 4) according to real-world evidence using data of MASK. A first meeting 526 
was held at the Pasteur Institute, Paris (December 3, 2018) to provide guidance for their 527 
development. 528 
This observational study made it possible to differentiate OAH and INCS, confirming known 529 
data, (34) and was able to differentiate between OAH. LEVOCET was found to be the most 530 
effective OAH confirming clinical experience. On the other hand, CETI appeared not to have 531 
been as effective. However, there were a large number of generics for CETI and this could be 532 
studied when more users will be available.  This study could also differentiate the three 533 
medications containing INCS: FF, MF and MP-AZeFlu and confirm previous studies (35)(36) 534 
extending our understanding of how AR treatment is used. RCTs showed that MP-AzeFlu is 535 
more effective than single components available in pharmacies (37) or components using the 536 
same formulation (38).    537 
The same trends for INCS-containing medications were observed for VAS global measured, 538 
eye, asthma and work. However, the percentages of well-controlled, controlled and poorly-539 
controlled days differed indicating the independence of data already observed. Moreover, data 540 
on work are extremely important to facilitate an economic evaluation of treatments. 541 
 542 
An important result is that VAS on day 1 was higher than any other consecutive/non-543 
consecutive day. This indicates that patients start using the App when symptoms are 544 
uncontrolled. This is one specificity of analysing app data and should be considered in studies 545 
that assess the control of allergic diseases in relation to risk factors such as air pollutants and 546 
allergen exposure. 547 
 548 
Conclusions 549 
Real world data (RWD) and real-world evidence (RWE) are playing an increasing role in health 550 
care decisions supporting clinical trial designs and observational studies to generate innovative 551 
and new treatment approaches. These data hold potential o answer questions previously thought 552 
infeasible (39) such as the true patient’s attitude towards treatment.  This observational study 553 
shows highly consistent results between different outc mes (VAS levels) and brings novel 554 
concepts for the management of allergic diseases. When the patient experiences increased 555 
symptom, indicating a loss of control, he/she increases the number of medications used that day. 556 
A total behavioural disconnection was found since most patients treat themselves on-demand 557 
when they are not controlled whereas the vast majority f physicians prescribe long-term 558 














management. The results of this paper will be of importance for the implementation of the 560 
MASK Good Practice recently recognized by DG Santé. 561 
 562 
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Table 1. Country and number of users recording Visual Analogue Scale score using the 686 
Allergy Diary in the full data set 687 
 688 
Country VAS measurements (days)  
 1             2 to 7 8 to 14 >14 Total 
Austria 226 (56.6%) 121 16 36 399 
Australia  49 (49.0%) 30 10 11 100 
Belgium 48 (49.5%) 35 5 9 97 
Brazil  572 (55.9%) 323 67 62 1024 
Canada 6 (35.3%) 7 3 1 17 
Czech Republic  1 (20.0%) 0 1 3 5 
Denmark 37 (45.1%) 29 4 12 82 
Finland 117 (44.8%) 93 25 26 261 
France 319 (61.3%) 147 19 35 520 
Germany  208 (39.8%) 141 35 139 523 
Greece 47 (23.7%) 43 24 84 198 
Italy 554 (44.6%) 389 87 213 1243 
Lithuania 59 (17.7%) 89 52 134 334 
Mexico  101 (13.0%) 207 128 343 779 
Netherland 167 (53.9%) 94 23 26 310 
Poland 286 (54.9%) 159 28 48 521 
Portugal 647 (49.2%) 505 64 100 1316 
Spain  129 (30.5%) 124 53 117 423 
Sweden 33 (39.3%) 34 6 11 84 
Switzerland  247 (64.0%) 111 11 17 386 
Turkey  81 (52.6%) 42 10 21 154 
UK 148 (42.8%) 104 46 48 346 
Total   4082 (44.7%) 2827 (31.0%) 717 (7.9%) 1496 (16.4%) 9122 
 689 














Table 2: Results of VAS global measured  691 
  Day 1  Full set (96,533 days)  
  N days 
  
Median [p25-p75]  N days [users] Median [p25-p75] Mean 
number of 
days per user 
No treatment  4991 34 [10-60]  52706 [6236] 8 [0-26] 8.45 
Bilastine*  128  48 [19-69.5]  1563 [261]  16 [6-37] 6.00 
Cetirizine*  350 52 [28-70]  2169 [545]  22 [9-50]  4.00 
Desloratadine*   300 50 [26-71]  2085 [504] 21 [8-46] 4.14 
Ebastine*  115  50 [26-72]  980 [201] 23 [9-48] 4.88 
Fexofenadine*   112  55 [32.5-71.5]  1128 [183] 14 [8-35] 6.17 
Levocetirizine*  149 43 [16-67]  1512 [260] 14 [5-28] 5.81 
Loratadine*  175 49 [28-72]  1680 [344] 21 [10-39] 4.88 
Rupatadine*  66 49 [23-63]  1138 [146] 18 [5-36] 7.69 
FF  176  35 [19.5-58.5]  2182 [336]  5 [0-27]    6.49 
 + OAH 129 51 [22-66]  1317 [247] 21 [4-45]         5.33 
 + OAH + other 38  64 [49-77]  307 [80] 48 [24-63] 3.84 
 + other (no OAH) 84 53.5 [28-72]  968 [168] 23 [9-47] 5.76 
 + other INCS 7 50 [4-90]  113 [16] 61 [26-95] 7.06 
AzeFlu  155  37 [16-60]  2722 [303]  13 [3-29] 8.98 
 + OAH 49 58 [40-73]  994 [113] 17 [7-40] 8.72 
 + OAH + other 12 54 [26-80]  174 [33] 31 [9-60] 5.27 
 + other (no OAH) 37 40 [21-65]  871 [98] 22 [11-42] 8.89 
 + other INCS 7 50 [33-77]  193 [21] 36 [12-73] 8.39 
MF  192  36.5 [16.5-59.5]  3420 [409]  15 [5-28] 7.92 
 + OAH 144 48 [23-68]  2181 [284] 17 [8-37] 7.68 
 + OAH + other 64 61.5 [33.5-75]  914 [114] 26 [14-49] 8.02 
 + other (no OAH) 83 53 [26-68]  1158 [167] 26 [9-45] 6.93 
 + other INCS 7 33 [0-77]  113 [21] 20 [6-79] 5.38 
FP  33  44 [30-65]  156 [55]  23.5 [3.5-52] 2.83 
 + OAH 34 56 [40-67]  305 [64] 19 [10-46] 4.77 
 + OAH + other 14 52.5 [45-80]  60 [21] 54 [24.5-82.5] 2.89 
 + other (no OAH) 13 41 [31-59]  121 [22] 22 [18-41] 5.50 
 + other INCS 3 4 [0-65]  127 [11] 22 [8-48] 11.55 
*: monotherapy 692 
FF: Fluticasone Furoate, FP: Fluticasone Propionate, MF: Mometasone Furoate, AZeFlu: 693 
Azelastine-Fluticasone Propionate 694 















Table 3. Day 1 versus non-consecutive days  697 
  Day 1  1
st
 non-consecutive day Other non-consecutive day P value* 
  N  VAS global, 
median [p25-p75] 
 N VAS global, 
median [p25-p75] 
N VAS global, 
median [p25-p75] 




All days  4132 34 [12-60]  4132 25 [7-51] 24680 12 [2-32]  <0.001 
No treatment 2214 26 [7-51]  2154 18 [4-44] 13651 8 [0-24]  <0.001 
AzeFlu  162 44 [19-69]  187 26 [9-55] 1566 17 [6-35]  <0.001 
Other INCS 
treatment 
555 43 [22-64]  601   30 [11-55] 3403 17 [6-38]  <0.001 
*Statistical analysis by Wilcoxon and Mann-Whitney test  698 
p25: 25
th
 percentile; p75: 75
th
 percentile 699 














Figure 1. Flow-chart of the study population 701 
Figure 2: Percentage of days in each category of INCS treatment (first day and full data set) 702 





























































































































































































All users reporting VAS
Untreated days Days with FF, FP, MF 
or AzeFlu
Other treatment Not studied
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Table 1 online: Variations in VAS global levels within the same day   
   VAS global, median [p25-p75] P value* 









All days 1,576 18 [4-45] 22 [6-50] 0.01 
Days without treatment 866 14 [0-36] 17 [3-42] 0.005 
Days with AzeFlu treatment 140 13 [4-41.5] 14 [4.5-53] 0.58 
Days with  other INCS treatment 177 29 [8-51] 25 [9-54] 0.90 
*Statistical analysis by Wilcoxon and Mann-Whitney test  















Figure 1 online: The Allergy Diary 
Figure 2 online: Groups of users studied and excluded in the first analysis 
 
Figure 3 online. Age distribution 
 
Figure 4 online. VAS reporting trajectories in French users (n=520 users, 3,114 days) 
 
Figures 5A, B, C online: Percentage of days in each category of treatment for VAS “eye”, 
“asthma” and “work” (full dataset) 
 
